Résumé
There is limited real-world information on the impact of adjuvant and neoadjuvant anti-HER2-targeted treatments on patterns of recurrence and outcomes of patients with HER2+ metastatic breast cancer. This article reports on how anti-HER2 targeted treatment in the early setting impacts overall and progression-free survival under first-line treatment of patients with metastatic HER2+ breast cancer.